PRMT5 and breast cancer: These findings prompted us to investigate the role of PRMT5 in WNT/β‐CATENIN signalling by examining expression of pathway antagonists including AXIN1, AXIN2, WIF1, DKK1‐4 and SFRP1‐5 in breast cancer cell lines.